River Stone Biotech has strengthened its IP position on their ability to use biology to replace difficult synthetic chemistry.

A new US patent grant, the first of a new patent family, gives the company protection on its unique approach to bioconversion across a range of products. It covers the use of an engineered microbe to improve in vivo conversion of thebaine and oripavine.

At River Stone Biotech, we combine cutting-edge synthetic biology with proven chemical processing to set new standards in molecule manufacturing.

River Stone’s proprietary platform uses flexible intermediates to produce a broad portfolio of specialty molecules. They can cost-effectively produce complex small molecules and fatty acid derivatives both for use as precursors and as final APIs (active pharmaceutical ingredients).

Next >